Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy
This article was originally published in The Pink Sheet Daily
Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.
You may also be interested in...
Ranbaxy is partnered with another Indian drug maker, Zenotech, in its foray into biosimilar development.
Deputy Sectary to leave after five and a half years with department; no successor announced.
Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.